Increasing Prevalence of Cancer and Commercialization and Distribution of New Products to Augment Growth of Companion Diagnostics Market

 


Companion diagnostics is a clinically established diagnostic tool used in conjunction with a therapeutic agent to identify the applicability of that drug to an individual patient. Companion diagnosis is generally the last step of drug management and usually involves a process of screening, evaluating, and prescribing medication based on the findings of companion diagnostics. A companion diagnose determines whether a particular drug therapy is suitable for the patient in terms of safety, toleration, and response to treatment. It is basically an advanced form of drug management that focuses on evaluating and implementing personalized treatment plans based on known medical issues and considerations.

Market Dynamics

Increasing prevalence of cancer is expected to propel growth of the global companion diagnostics market over the forecast period. For instance, according to the American Cancer Society, in 2020, around 276,480 new cases of invasive breast cancer will be diagnosed in women and the disease will lead to around 42,170 deaths, in the U.S. Moreover, increasing development and commercialization of new products is also expected to aid in growth of the market. For instance, in November 2020, LabCorp announced an expanded agreement with BML, a leading Japanese provider of clinical laboratory testing services, to provide development and delivery of companion diagnostics in Japan.

Increasing commercialization and distribution of new products is expected to offer lucrative growth opportunities for players in the global companion diagnostics market. For instance, in August 2020, HTG Molecular Diagnostics, Inc., a life science company, signed a commercialization and distribution agreement with QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V., for distribution and commercialization of companion diagnostic assays based on HTG EdgeSeq, HTG’s novel RNA platform.

Competitive Analysis

Major players in the global companion diagnostics market include, Abbott Laboratories, Agendia N.V., Agilent Technologies, Inc., BioGenex Laboratories Inc., bioMérieux SA, LabCorp, GE Healthcare Ltd., Genomic Health, Inc., Life Technologies Corporation, Qiagen N.V., Resonance Health Analysis Services Pty Ltd., F. Hoffmann-La Roche AG, Danaher Corporation, Qiagen N.V., Illumina, Inc., Myriad Genetics Inc., Myriad Genetics, Inc., Foundation Medicine, Inc., and Siemens Healthineers.

Major players in the global companion diagnostics market are focused on development and commercialization of new products to expand their product portfolio. For instance, in November 2020, Qiagen N.V. collaborated with BioNTech to develop and commercialize a tissue-based companion diagnostic, to be used with investigational cancer treatment BNT113, which identifies patients with squamous cell carcinoma of the head and neck (SCCHN) that are caused by specific infections by human papilloma virus.


Comments

Post a Comment

Popular posts from this blog

Increasing Consumption and Production of Fertilizers to Upsurge the Growth of the Agrochemicals Market

Image
  Agrochemical products are those chemicals that are used to increase the production of an agricultural environment. Agrochemical chemicals typically include pesticides, fertilizers, lime precursors, acidizing and alkalizing agents (all of which are designed to alter the normal pH level of the soil), lime stabilizers, and other nutrients that are required for plant growth. These chemicals are widely used by farmers and are crucial to the functioning of modern agriculture. The use of these chemicals presents a number of concerns both from the perspective of the environment and the human body. The increasing need for improving crop production due to the growing concern of food security and lack of arable land is fueling the growth of agrochemicals market . Growing advancement in technology is raising adoption of advanced and sustainable farming practices which is again propelling the growth of the market. The increasing population coupled with the growing usage of fertilizers aroun...
Read more

High Prevalence of Cancer and R&D in Anti-Cd39 Antibodies to Augment Growth of Anti-body Coupled T Receptor Therapy Market

Image
  Antibody-Coupled T cell Receptor (ACTR) is an autologous engineered T cell therapy that combines the Fc receptor, CD16, with endogenous T cell signaling and costimulatory domains. It is combined with tumor-targeting antibodies to exert potent anti-tumor immune responses and eliminate cancerous cells. ACRT has demonstrated potential in the treatment of multiple myeloma and HER2+ advanced cancers. Market Dynamics R&D in anti-CD39 antibodies is expected to propel growth of the Anti-body Coupled T Receptor Therapy Market . For instance, in December 2020, Arcus Biosciences, Inc. expanded its existing partnership with WuXi Biologics, a developer of biologics technology platforms, for R&D in anti-CD39 antibodies using WuXi Bio’s proprietary technology. Moreover, high prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 ...
Read more

Increasing Prevalence of Muscular Dystrophy to Augment the Muscular Dystrophy Treatment Market Growth

Image
  Muscular dystrophy is a common disease that causes muscles to become weaker and unable to continue to develop properly. Because it often affects young children as well as adults, it can be difficult to detect. However, once symptoms are noticed, steps must be taken to prevent the disease. There are many treatment options available for muscular dystrophy. The severity of the disease will determine what type of treatment is best for your situation. Muscular dystrophy treatment involves breathing aids, therapy, surgery, or medication, which may help maintain function, but life span is often shortened. Market Dynamics: Increasing prevalence or incidence of muscular dystrophy, especially in the North America, is expected to propel the growth of the muscular dystrophy treatment market . For instance, one in 3,500 male babies born worldwide are affected with Duchenne muscular dystrophy (DMD), according to the National Organization for Rare Disorders. Moreover, in 2019, around 349 ne...
Read more